Avacta Group, a biotechnology company developing novel cancer immunotherapies based on its proprietary Affimer platform, has entered a collaboration and option agreement with ADC Therapeutics SA, a clinical-stage oncology-focused biotechnology company pioneering the development of highly potent and targeted antibody-drug conjugates for patients suffering from haematological malignancies and solid tumors. The agreement is to develop Affimer-drug conjugates combining Avacta’s Affimer technology wi...